Published: 14 June 2019
Author(s): Antonio Tursi, Giammarco Mocci, Roberto Faggiani, Leonardo Allegretta, Nicola Della Valle, Antonio de Medici, Giacomo Forti, Marilisa Franceschi, Antonio Ferronato, Sara Gallina, Giuseppina Grasso, Tiziana Larussa, Francesco Luzza, Roberto Lorenzetti, Antonio Penna, Stefano Rodino', Ladislava Sebkova, Angelo Lauria, Simona Piergallini, Giuseppe Pranzo, Stefano Scorza, Costantino Zampaletta, Marcello Picchio, Walter Elisei
Issue: June 2019
Section: Original Article

Italian data currently available in managing ulcerative colitis (UC) and Crohn's disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary centers. The present study aimed to assess the real-life efficacy and safety of VDZ to achieve remission in inflammatory bowel diseases (IBD) outpatients in primary gastroenterology centers.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.